Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 26.25 is 65% above its 5-year average of 15.95, near the low end of its 5-year range (2.03–119.17).
As of the fiscal period ended Tuesday, June 30, 2026. 60.08% above its 12-month average of 16.40.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 26.25.
CURRENT RATIO
26.25
CURRENT RATIO AVG TTM
16.40
CURRENT RATIO AVG 3Y
7.84
CURRENT RATIO AVG 5Y
15.95
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+60.08%
CURRENT VS 3Y AVG
+235.02%
CURRENT VS 5Y AVG
+64.57%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.57
median of 737 covered companies
CURRENT VS SECTOR MEDIAN
+635.27%
vs the sector median at left
Pasithea Therapeutics Corp.
Market Cap
$14.95M
Current Ratio
26.25
TTM Avg
16.40
3Y Avg
7.84
5Y Avg
15.95
Market Cap
$15.10M
Current Ratio
0.79
TTM Avg
1.41
3Y Avg
2.88
5Y Avg
3.31
Market Cap
$15.42M
Current Ratio
1.24
TTM Avg
4.22
3Y Avg
12.60
5Y Avg
18.98
Market Cap
$14.44M
Current Ratio
1.84
TTM Avg
8.58
3Y Avg
10.61
5Y Avg
11.66
Market Cap
$15.75M
Current Ratio
1.11
TTM Avg
2.09
3Y Avg
1.19
5Y Avg
1.02
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | $14.95M | 26.25 | 16.40 | 7.84 | 15.95 |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.10M | 0.79 | 1.41 | 2.88 | 3.31 |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.56M | N/A | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.42M | 1.24 | 4.22 | 12.60 | 18.98 |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.44M | 1.84 | 8.58 | 10.61 | 11.66 |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.75M | 1.11 | 2.09 | 1.19 | 1.02 |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | 4.37 | 1.46 | 1.74 | 1.95 |
| BioCardia, Inc. (BCDA)vs › | $16.07M | 2.09 | 1.13 | 1.21 | 2.30 |
| IN8bio, Inc. (INAB)vs › | $13.89M | 8.21 | 6.45 | 5.32 | 7.60 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.89M | 0.84 | 0.51 | 4.20 | 6.42 |
Current Ratio
26.25
Quick Ratio
26.25
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 26.25 |
| 2026-03-31 | 35.40 |
| 2025-12-31 | 11.35 |
| 2025-09-30 | 4.02 |
| 2025-06-30 | 4.97 |
| 2025-03-31 | 3.84 |
| 2024-12-31 | 6.58 |
| 2024-09-30 | 14.81 |
| 2024-06-30 | 6.20 |
| 2024-03-31 | 5.35 |
| 2023-12-31 | 6.34 |
| 2023-09-30 | 10.16 |
| 2023-06-30 | 12.58 |
| 2023-03-31 | 14.66 |
| 2022-12-31 | 18.15 |
| 2022-09-30 | 29.37 |
| 2022-06-30 | 51.17 |
| 2022-03-31 | 117.48 |
| 2021-12-31 | 119.17 |
| 2021-09-30 | 39.83 |
| 2021-06-30 | 2.03 |
| 2021-03-31 | 4.76 |
| 2020-12-31 | 37.55 |
| 2020-09-30 | 0.00 |
